Russian biopharmaceutical company Nanolek has registered Cegardex, its quadrivalent human papillomavirus (HPV) vaccine, in Armenia. This marks the vaccine’s first registration outside Russia. The registration was granted under the mutual recognition procedure for medicinal products established within the Eurasian Economic Union (EAEU).

Cegardex is the first Russian-made quadrivalent HPV vaccine designed to prevent diseases caused by HPV types 6, 11, 16, and 18. The vaccine was developed by Nanolek in partnership with the research and manufacturing company Kombiotech. Full-cycle production has been established at Nanolek’s biomedical manufacturing facility in the Kirov Region, Russia. The vaccine entered the Russian market in September 2026.

Armenia introduced HPV vaccination into its national immunization program in 2017. According to data from Armenia’s Ministry of Health published by UNICEF, HPV vaccination coverage among girls in the primary target group increased from 8% in 2018 to 34% in 2024, reaching 40% by June 2025. The World Health Organization’s global strategy aims to ensure that 90% of girls are fully vaccinated against HPV by the age of 15 by 2030. Cervical cancer remains a significant public health concern in Armenia, ranking as the second most common cancer among women aged 15–44.

In Armenia, as in Russia, Cegardex is approved for use in both males and females aged 9 to 45.

“Meeting the needs of the Russian healthcare system remains our absolute priority. At the same time, we are working to secure registration of our vaccine outside Russia, primarily in EAEU member states. In addition to Armenia, applications for recognition of the vaccine’s registration have been submitted in Belarus, Kazakhstan, and Kyrgyzstan. We expect the procedure to be completed in these countries following Armenia,” said Evgeny Barinov, CEO of Nanolek.

In Russia, the first batch of 30,000 doses of Cegardex was released for commercial distribution in September 2026. Nanolek plans to manufacture 600,000 doses of the vaccine by the end of 2026. In 2027, following the launch of a second production facility, the company’s annual HPV vaccine manufacturing capacity will exceed 3 million doses.